PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial Designed to Support Potential Accelerated Approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Benzinga Newsdesk - Mar 4, 2024, 7:04AM